New STH 2023 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

This Editorial continues our now standard approach, to announce our newest Journal Impact Factor (IF) and other journal metrics, upon release of the latest IF.[1] [2] [3]

Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2024

• References

• 1 Favaloro EJ. New STH (2020) Impact Factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2021; 47 (07) 745-753
• 2 Favaloro EJ. New Seminars in Thrombosis and Hemostasis (STH) 2021 Impact Factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2022; 48 (06) 634-642
• 3 Favaloro EJ. New Seminars in Thrombosis and Hemostasis 2022 Impact Factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2023; 49 (07) 661-669
• 4 WHO. COVID-19 dashboard. Accessed 27 June 2024 at: https://data.who.int/dashboards/covid19/cases
• 5 WHO. COVID-19 vaccination, World data. Accessed 27 June 2024 at: https://data.who.int/dashboards/covid19/vaccines?n=o
• 6 National Library of Medicine/National Center for Biotechnology Information/PubMed.com. Accessed 30 June 2023 at: https://pubmed.ncbi.nlm.nih.gov/?term=covid-19
• 7 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-Part I. Semin Thromb Hemost 2020; 46 (07) 757-762
• 8 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): Part II. Semin Thromb Hemost 2021; 47 (04) 333-337
• 9 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-Part III. Semin Thromb Hemost 2022; 48 (01) 3-7
• 10 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-Part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
• 11 Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2021; 47 (05) 467-476
• 12 Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2022; 48 (05) 502-513
• 13 Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2023; 49 (05) 417-426
• 14 Favaloro EJ. 2024 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2024; (e-pub ahead of print)
• 15 Favaloro EJ. The Journal Impact Factor: don't expect its demise any time soon. Clin Chem Lab Med 2009; 47 (11) 1319-1324
• 16 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008; 34 (01) 7-25
• 17 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
• 18 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
• 19 Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021; 47 (07) 759-774
• 20 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
• 21 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021; 47 (04) 372-391
• 22 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
• 23 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021; 47 (04) 400-418
• 24 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
• 25 Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The pathophysiological role of platelet-derived extracellular vesicles. Semin Thromb Hemost 2023; 49 (03) 279-283
• 26 Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection control. Semin Thromb Hemost 2022; 48 (02) 174-187
• 27 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022; 48 (04) 446-458
• 28 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
• 29 Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022; 48 (05) 514-528
• 30 Lepedda AJ, Nieddu G, Piperigkou Z, Kyriakopoulou K, Karamanos N, Formato M. Circulating heparan sulfate proteoglycans as biomarkers in health and disease. Semin Thromb Hemost 2021; 47 (03) 295-307
• 31 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
• 32 Vlodavsky I, Barash U, Nguyen HM, Yang SM, Ilan N. Biology of the heparanase-heparan sulfate axis and its role in disease pathogenesis. Semin Thromb Hemost 2021; 47 (03) 240-253
• 33 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
• 34 Oshima K, King SI, McMurtry SA, Schmidt EP. Endothelial heparan sulfate proteoglycans in sepsis: the role of the glycocalyx. Semin Thromb Hemost 2021; 47 (03) 274-282
• 35 Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost 2021; 47 (04) 392-399
• 36 Alamin AA. The role of red blood cells in hemostasis. Semin Thromb Hemost 2021; 47 (01) 26-31
• 37 Lippi G, Henry BM, Favaloro EJ. Mean platelet volume predicts severe COVID-19 illness. Semin Thromb Hemost 2021; 47 (04) 456-459
• 38 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
• 39 Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 2016; 42 (04) 356-365
• 40 Franchini M, Cappello E, Valdiserra G. et al. Investigating a signal of acquired hemophilia associated with COVID-19 vaccination: a systematic case review. Semin Thromb Hemost 2023; 49 (01) 15-26
• 41 Abate V, Casoria A, Rendina D. et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; 48 (01) 100-108
• 42 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
• 43 Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022; 48 (02) 206-218
• 44 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
• 45 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
• 46 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-Part I. Semin Thromb Hemost 2022; 48 (08) 871-874
• 47 Nadir Y, Lisman T. Hemostatic and nonhemostatic effects of heparan sulfate proteoglycans. Semin Thromb Hemost 2021; 47 (03) 238-239
• 48 Favaloro EJ, Lippi G. Editorial compilation X. Semin Thromb Hemost 2021; 47 (07) 754-758
• 49 Schulman S. Recent advances in thrombosis and hemostasis-Part VII. Semin Thromb Hemost 2021; 47 (06) 621-622
• 50 Kwaan HC, Walsh M, Lindholm PF, Othman M. Emerging use of viscoelastography in thrombosis and hemostasis: a challenge to conventional coagulation tests? Part I: the use of thromboelastography and thromboelastometry in the assessment of hemostatic function. Semin Thromb Hemost 2022; 48 (07) 767-768
• 51 Favaloro EJA. 2018 Update on the editorial and publication policy of Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
• 52 Favaloro EJ. A short history of Thrombosis and Hemostasis: part I (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (05) 521-525
• 53 Favaloro EJ. A short history of thrombosis and hemostasis: part II (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (08) 826-830
• 54 Favaloro EJ. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part II. Semin Thromb Hemost 2023; 49 (03) 212-216
• 55 Favaloro EJ. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part III. Semin Thromb Hemost 2024; 50 (01) 4-7
• 56 Favaloro EJ. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part IV. Semin Thromb Hemost 2024; 50 (05) 677-681
• 57 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707
• 58 Favaloro EJ. von Willebrand factor (VWF) collagen binding (activity) assay (VWF:CBA) in the diagnosis of von Willebrand's disorder (VWD): a 15-year journey. Semin Thromb Hemost 2002; 28 (02) 191-202